Athenex establishment of a joint venture with Guangzhou Xiangxue Pharmaceutical Co., Ltd

Athenex Inc. in connection with the establishment of a joint venture with Xiangxue Life Sciences, a wholly owned subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd., for the research, development and commercialization of T-cell receptor-engineered T cells, a cancer immunotherapy technology. Axis Therapeutics Limited, the new joint venture to be established and owned initially as 55% by Athenex and 45% by Xiangxue Life Sciences, has in-licensed the worldwide (excluding mainland China) rights of all the intellectual properties and know-how of the TCR-T immunotherapy technology from Xiangxue Life Sciences, subject to certain closing conditions and approvals. Pursuant to the terms of the license agreement and shareholders agreement, Athenex will issue US$5 million worth of Athenex common stock to Xiangxue Life Sciences as an upfront payment and Athenex will contribute US$30 million in cash to the joint venture. Perceptive Advisors, an investment manager with a deep history in supporting biotechnology companies, will provide a combination of equity and debt financing to support Athenex's operations and continued development, including pipeline expansion initiatives. Perceptive Advisors will invest US$100 million in Athenex, comprised of US$50 million in equity and US$50 million in debt.